A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population
- 19 April 2016
- journal article
- adaptive clinical-trial
- Published by Elsevier BV in Contemporary Clinical Trials
- Vol. 48, 153-165
- https://doi.org/10.1016/j.cct.2016.04.004
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Bayesian dose escalation in oncology with sharing of information between patient populationsContemporary Clinical Trials, 2015
- Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.Journal of Clinical Oncology, 2015
- Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells.Journal of Clinical Oncology, 2015
- 475. Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALLMolecular Therapy, 2015
- Adaptive designs for identifying optimal biological dose for molecularly targeted agentsClinical Trials, 2014
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trialsClinical Trials, 2013
- Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline frameworkContemporary Clinical Trials, 2012
- Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity OutcomesBiometrics, 2009
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2009
- Dose‐Finding Based on Efficacy–Toxicity Trade‐OffsBiometrics, 2004